IQVIA Holdings/$IQV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About IQVIA Holdings

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Ticker

$IQV
Sector

Primary listing

NYSE

Employees

90,000

IQVIA Holdings Metrics

BasicAdvanced
$34B
29.01
$6.92
1.32
-

What the Analysts think about IQVIA Holdings

Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.

Bulls say / Bears say

Analysts noted Q2 2025 results point to a potential inflection in biopharma demand, supporting sustainable growth into 2026 (Reuters)
Technology & Analytics Solutions revenue grew 8.9% year-over-year in Q2 2025, outpacing companywide growth and underscoring strength in IQVIA’s high-margin analytics business (Business Wire)
IQVIA repurchased $607 million of common stock in Q2 2025, with over $1 billion repurchased year-to-date, reflecting strong free cash flow generation and management confidence (Business Wire)
Some analysts caution that clinical trial demand has not fully recovered, which could limit growth in the Research & Development segment (Reuters)
As of June 30, 2025, IQVIA’s net debt stood at $13.45 billion with a net leverage ratio of 3.61x trailing EBITDA, posing financial risk if interest rates rise further (Business Wire)
Geopolitical risks, including potential U.S. tariffs and trade tensions with China, could disrupt clients’ supply chains and constrain IQVIA’s global operations (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

IQVIA Holdings Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IQVIA Holdings Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IQV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs